Firstpost
  • Home
  • Video Shows
    Vantage Firstpost America Firstpost Africa First Sports
  • World
    US News
  • Explainers
  • News
    India Opinion Cricket Tech Entertainment Sports Health Photostories
  • Asia Cup 2025
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
Trending:
  • Charlie Kirk shot dead
  • Nepal protests
  • Russia-Poland tension
  • Israeli strikes in Qatar
  • Larry Ellison
  • Apple event
  • Sunjay Kapur inheritance row
fp-logo
Hetero gets DCGI nod to launch anti-viral drug Remdesivir under brand name Covifor for COVID-19 treatment
Whatsapp Facebook Twitter
Whatsapp Facebook Twitter
Apple Incorporated Modi ji Justin Trudeau Trending

Sections

  • Home
  • Live TV
  • Videos
  • Shows
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Health
  • Tech/Auto
  • Entertainment
  • Web Stories
  • Business
  • Impact Shorts

Shows

  • Vantage
  • Firstpost America
  • Firstpost Africa
  • First Sports
  • Fast and Factual
  • Between The Lines
  • Flashback
  • Live TV

Events

  • Raisina Dialogue
  • Independence Day
  • Champions Trophy
  • Delhi Elections 2025
  • Budget 2025
  • US Elections 2024
  • Firstpost Defence Summit
  • Home
  • India
  • Hetero gets DCGI nod to launch anti-viral drug Remdesivir under brand name Covifor for COVID-19 treatment

Hetero gets DCGI nod to launch anti-viral drug Remdesivir under brand name Covifor for COVID-19 treatment

Press Trust of India • June 22, 2020, 09:05:23 IST
Whatsapp Facebook Twitter

The drug has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease, the company said.

Advertisement
Subscribe Join Us
Add as a preferred source on Google
Prefer
Firstpost
On
Google
Hetero gets DCGI nod to launch anti-viral drug Remdesivir under brand name Covifor for COVID-19 treatment

New Delhi: Drug firm Hetero on Sunday said it has received approval from regulator DCGI to launch investigational antiviral drug Remdesivir for the treatment of COVID-19. Domestic pharma firm Glenmark Pharmaceuticals had on Saturday launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 at a price of about Rs 103 per tablet Hetero has received the manufacturing and marketing approval for Remdesivir from the Drug Controller General of India (DCGI) for the treatment of COVID-19, it said in a statement.  Hetero’s generic version of Remdesivir will be marketed under the brand name ‘Covifor’ in India. The drug will be available in 100 mg vial (injectable) which has to be administered intravenously in a hospital setting under the supervision of a healthcare practitioner, it said. [caption id=“attachment_8324871” align=“alignleft” width=“380”] ![Representational image. Image by Willfried Wende from Pixabay. ](https://images.firstpost.com/wp-content/uploads/2020/05/Remdesivir.-1.jpg) Representational image. Image by Willfried Wende from Pixabay.[/caption] Asked about the price of the drug, Hetero Group of Companies MD Vamsi Krishna Bandi told news agency PTI it will be in the range of Rs 5,000-6,000 per dose. Currently, the drug is being manufactured at the company’s formulation facility in Hyderabad. The active pharmaceutical ingredient (API) is being made in the firm’s Visakhapatnam facility, he added. The drug will be available only through hospitals and government, and not the retail channel, Vamsi said. The company is focused on providing one lakh doses in the next few weeks, and the production can be ramped up based on demand, he added. Follow Latest Updates on Coronavirus Outbreak here The drug has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children, hospitalised with severe symptoms of the disease, the company said. “In the light of increasing COVID-19 cases in India, the approval of ‘Covifor’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes. Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country,“Hetero Group of Companies Chairman B Partha Saradhi Reddy said. The company is prepared for ensuring enough stocks to cater to the present needs, he added. The product is being launched under a licensing agreement with Gilead Sciences Inc to expand access to COVID-19 treatment in low and middle-income countries, Hetero said. In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences had entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of Remdesivir. The medicine has been issued an Emergency Use Authorization (EUA) by the United States Food and Drug Administration (USFDA) to treat COVID-19 patients.

Tags
NewsTracker FDA DCGI Gilead coronavirus treatment remdesivir COVID 19 Favipiravir
End of Article
Latest News
Find us on YouTube
Subscribe
End of Article

Impact Shorts

News18 SheShakti 2025: Voices of cinema, sport and music redefine nation-building

News18 SheShakti 2025: Voices of cinema, sport and music redefine nation-building

At News18 SheShakti 2025 Delhi, women from sports, cinema, and music discussed breaking barriers. Kriti Sanon and Sanya Malhotra focused on equity in cinema, Mira Erda and Ashalata Devi on sports challenges, and Kavita Krishnamurti stressed humility and perseverance for lasting success.

More Impact Shorts

Top Stories

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

From governance to tourism, how Gen-Z protests have damaged Nepal

From governance to tourism, how Gen-Z protests have damaged Nepal

Did Russia deliberately send drones into Poland’s airspace?

Did Russia deliberately send drones into Poland’s airspace?

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

Charlie Kirk, shot dead in Utah, once said gun deaths are 'worth it' to save Second Amendment

From governance to tourism, how Gen-Z protests have damaged Nepal

From governance to tourism, how Gen-Z protests have damaged Nepal

Did Russia deliberately send drones into Poland’s airspace?

Did Russia deliberately send drones into Poland’s airspace?

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Netanyahu ‘killed any hope’ for Israeli hostages: Qatar PM after Doha strike

Top Shows

Vantage Firstpost America Firstpost Africa First Sports
Latest News About Firstpost
Most Searched Categories
  • Web Stories
  • World
  • India
  • Explainers
  • Opinion
  • Sports
  • Cricket
  • Tech/Auto
  • Entertainment
  • IPL 2025
NETWORK18 SITES
  • News18
  • Money Control
  • CNBC TV18
  • Forbes India
  • Advertise with us
  • Sitemap
Firstpost Logo

is on YouTube

Subscribe Now

Copyright @ 2024. Firstpost - All Rights Reserved

About Us Contact Us Privacy Policy Cookie Policy Terms Of Use
Home Video Shorts Live TV